Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients.
Goto H, Iseri K, Hida N.
Nephrol Dial Transplant · research-article; journal article · DOI 10.1093/ndt/gfad248 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för pemafibrate. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
39 träffarRole of PPARα in inflammatory response of C2C12 myotubes.
Shimizu Y, Hamada K, Guo T, Hasegawa C, Kuga Y, Takeda K, Yagi T, Koyama H, Takagi H, Aotani D, Kataoka H, Tanaka T.
Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2023.149413Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia.
Hida Y, Imamura T, Kinugawa K.
J Clin Med · research-article; journal article · DOI 10.3390/jcm12216915Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage.
Nomoto H, Kito K, Iesaka H, Handa T, Yanagiya S, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Sakuma I, Nakamura A, Atsumi T.
Diabetol Metab Syndr · research-article; journal article · DOI 10.1186/s13098-023-01187-7Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H.
Int J Mol Sci · review-article; review; journal article · DOI 10.3390/ijms242015473Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
Nishida M, Horio T, Fukuda Y, Hayakawa Y, Tateishi Y, Akai M, Emoto M, Hasegawa T, Imanishi M.
Int J Clin Pharmacol Ther · journal article; observational study · DOI 10.5414/cp204408A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
Yamada-Shimizu M, Tamaki N, Kurosaki M, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Nobusawa T, Matsumoto H, Keitoku T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N.
Intern Med · comparative study; research-article; journal article · DOI 10.2169/internalmedicine.2248-23Spatiotemporally quantitative in vivo imaging of mitochondrial fatty acid β-oxidation at cellular-level resolution in mice.
Matsumoto A, Matsui I, Uchinomiya S, Katsuma Y, Yasuda S, Okushima H, Imai A, Yamamoto T, Ojida A, Inoue K, Isaka Y.
Am J Physiol Endocrinol Metab · research support, non-u.s. gov't; journal article · DOI 10.1152/ajpendo.00147.2023Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion.
Kitamura S, Murao N, Yokota S, Shimizu M, Ono T, Seino Y, Suzuki A, Maejima Y, Shimomura K.
BMC Res Notes · research-article; journal article · DOI 10.1186/s13104-023-06489-7Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
Hirano T, Hayashi T, Sugita H, Tamasawa A, Goto S, Tomoyasu M, Yamamoto T, Ohara M, Terasaki M, Kushima H, Ito Y, Yamagishi SI, Mori Y.
J Diabetes Investig · research-article; randomized controlled trial; journal article · DOI 10.1111/jdi.14076A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia.
Katsuyama H, Yanai H, Adachi H, Hakoshima M.
Gastroenterology Res · research-article; journal article · DOI 10.14740/gr1656Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.
Khan MS, Ghumman GM, Baqi A, Shah J, Aziz M, Mir T, Tahir A, Katragadda S, Singh H, Taleb M, Ali SS.
Am J Cardiovasc Drugs · systematic review; network meta-analysis; journal article · DOI 10.1007/s40256-023-00593-6Effects of pemafibrate on left ventricular diastolic function in patients with type 2 diabetes mellitus: a pilot study.
Yamamoto K, Ohta Y, Taguchi A, Akiyama M, Nakabayashi H, Nagao Y, Ryoko H, Wada Y, Yamamoto T, Yano M, Tanizawa Y.
Diabetol Int · brief-report; journal article · DOI 10.1007/s13340-023-00645-xPemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?
Lee D, Tomita Y, Negishi K, Kurihara T.
Neural Regen Res · other; journal article · DOI 10.4103/1673-5374.360319Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.
Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, Yanagiya S, Miya A, Kameda H, Cho KY, Sakuma I, Manda N, Nakamura A, Atsumi T.
Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics15071838Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease.
Ishikawa T, Terai N, Igarashi T, Yamazaki S, Kobayashi T, Sato T, Iwanaga A, Sano T, Yokoyama J, Honma T.
Clin Exp Hepatol · research-article; journal article · DOI 10.5114/ceh.2023.127813Selective activation of PPARα maintains thermogenic capacity of beige adipocytes.
Egusa G, Ohno H, Nagano G, Sagawa J, Shinjo H, Yamamoto Y, Himeno N, Morita Y, Kanai A, Baba R, Kobuke K, Oki K, Yoneda M, Hattori N.
iScience · research-article; journal article · DOI 10.1016/j.isci.2023.107143Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.
Shinozaki S, Tahara T, Miura K, Lefor AK, Yamamoto H.
Life (Basel) · research-article; journal article · DOI 10.3390/life13061327Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
Takahashi Y, Seko Y, Yamaguchi K, Takeuchi K, Yano K, Kataoka S, Moriguchi M, Itoh Y.
J Gastroenterol Hepatol · journal article · DOI 10.1111/jgh.16222Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
Nakamura A, Kagaya Y, Saito H, Kanazawa M, Sato K, Miura M, Kondo M, Endo H.
J Atheroscler Thromb · other; published erratum; randomized controlled trial; journal article · DOI 10.5551/jat.er63659Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
Yamashita S, Rizzo M, Su TC, Masuda D.
Metabolites · review-article; review; journal article · DOI 10.3390/metabo13050626The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease-related cardiovascular diseases.
Chung HH.
Hepatol Res · letter · DOI 10.1111/hepr.13903Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
Horinouchi Y, Murashima Y, Yamada Y, Yoshioka S, Fukushima K, Kure T, Sasaki N, Imanishi M, Fujino H, Tsuchiya K, Shinomiya K, Ikeda Y.
Life Sci · journal article · DOI 10.1016/j.lfs.2023.121590Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Van Regemorter E, Jadoul M, Gillion V.
N Engl J Med · letter; comment · DOI 10.1056/nejmc2216470Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Oliva-Damaso N, Perazella MA.
N Engl J Med · letter; comment · DOI 10.1056/nejmc2216470Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Katakura Y, Shimoda M, Ohnishi M, Kusano T, Dan K, Isobe H, Wamata R, Iwamoto Y, Fushimi Y, Sanada J, Obata A, Kimura T, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H.
Nutr Metab Cardiovasc Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.numecd.2023.02.011Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome.
Iwakura T, Yasu T, Tomoe T, Ueno A, Sugiyama T, Otani N, Kawamoto S, Nakajima H.
J Clin Med · brief-report; journal article · DOI 10.3390/jcm12041481Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.
Sugimoto R, Iwasa M, Eguchi A, Tamai Y, Shigefuku R, Fujiwara N, Tanaka H, Kobayashi Y, Ikoma J, Kaito M, Nakagawa H.
Front Med (Lausanne) · research-article; journal article · DOI 10.3389/fmed.2023.1073025Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD).
Seki M, Nakano T, Tanaka S, Matsukuma Y, Funakoshi K, Ohkuma T, Kitazono T.
Clin Exp Nephrol · clinical trial protocol; journal article · DOI 10.1007/s10157-023-02322-4Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Iwasaki M, Suzuki H, Umezawa Y, Koshida T, Saito M, Fukuda H, Takahara H, Matsuzaki K, Suzuki Y.
Medicine (Baltimore) · research-article; journal article · DOI 10.1097/md.0000000000032818